Published in Anticancer Drugs on October 01, 1997
Advances in cancer therapy through the use of carbon nanotube-mediated targeted hyperthermia. Int J Nanomedicine (2011) 0.93
Photothermal treatment of liver cancer with albumin-conjugated gold nanoparticles initiates Golgi Apparatus-ER dysfunction and caspase-3 apoptotic pathway activation by selective targeting of Gp60 receptor. Int J Nanomedicine (2015) 0.85
Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics. Front Immunol (2015) 0.84
Albumin-based drug delivery: harnessing nature to cure disease. Mol Cell Ther (2016) 0.82
Phase II study of MTX-HSA in combination with cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma. Invest New Drugs (2006) 0.79
Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med (1994) 5.03
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst (1998) 4.43
Efficient transfer of highly resolved small DNA fragments from polyacrylamide gels to DBM paper. Gene (1980) 3.30
Dose: a critical factor in cancer chemotherapy. Am J Med (1980) 2.82
Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med (1975) 2.71
A successful system of scientific data audits for clinical trials. A report from the Cancer and Leukemia Group B. JAMA (1993) 2.60
The nature and control of infections in patients with acute leukemia. Cancer Res (1965) 2.55
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med (1988) 2.23
Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med (1974) 2.02
Establishment and characterization of monoclonal antibodies against an octahedral gallium chelate suitable for immunoscintigraphy with PET. J Nucl Med (1992) 1.99
Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science (1990) 1.93
A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil. Cancer Res (1978) 1.88
Clinical trials with adriamycin. Cancer (1971) 1.86
Spilled gallstones after laparoscopic cholecystectomy. A relevant problem? A retrospective analysis of 10,174 laparoscopic cholecystectomies. Surg Endosc (1998) 1.77
A lesson from Canada: Ontario's health insurance. N Engl J Med (1978) 1.76
Carcinoembryonic antigen: clinical correlation with chemotherapy for metastatic gastrointestinal cancer. Cancer (1974) 1.74
Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst (1988) 1.73
Controlled multicenter trial of laparoscopic transabdominal preperitoneal hernioplasty vs Shouldice herniorrhaphy. Early results. Surg Endosc (1996) 1.71
The Polycomb-group gene, extra sex combs, encodes a nuclear member of the WD-40 repeat family. EMBO J (1995) 1.69
Active immunotherapy with B.C.G. for recurrent malignant melanoma. Lancet (1973) 1.66
Complications of laparoscopic cholecystectomy in Switzerland. A prospective 3-year study of 10,174 patients. Swiss Association of Laparoscopic and Thoracoscopic Surgery. Surg Endosc (1998) 1.65
Plasma protein (albumin) catabolism by the tumor itself--implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hematol (1997) 1.60
Adjuvant chemotherapy in stage III colon cancer with 5-fluorouracil and levamisole versus 5-fluorouracil and leucovorin. Onkologie (2002) 1.58
Inflammatory cytokines in subarachnoid haemorrhage: association with abnormal blood flow velocities in basal cerebral arteries. J Neurol Neurosurg Psychiatry (2001) 1.53
Studies of patients in a laminar air flow unit. Cancer (1969) 1.49
Combination cancer therapy: Presidential address. Cancer Res (1972) 1.47
Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol (1983) 1.45
X-ray Monochromator with 2 x 10(8) Energy Resolution. J Synchrotron Radiat (1996) 1.44
Intensive combination chemotherapy and X-irradiation in Hodgkin's disease. Cancer Res (1967) 1.44
Gallium-68 chelate imaging of human colon carcinoma xenografts pretargeted with bispecific anti-CD44V6/anti-gallium chelate antibodies. J Nucl Med (1998) 1.43
Selection bias in clinical trials. J Clin Oncol (1985) 1.42
Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res (1983) 1.39
[Early results of the initial 100 laparoscopic hernia operations under peridural anesthesia]. Schweiz Med Wochenschr (1995) 1.39
Complex regulation of early paired expression: initial activation by gap genes and pattern modulation by pair-rule genes. Development (1993) 1.39
Preoperative Nyhus classification of inguinal hernias and type-related individual hernia repair. A case for diagnostic laparoscopy. Surg Laparosc Endosc (1997) 1.39
Effect of adriamycin on the cell cycle traverse and kinetics of cultured human lymphoblasts. Cancer Res (1976) 1.38
Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol (1988) 1.37
Combined cyclophosphamide vincristine, and prednisone therapy of malignant lymphoma. Cancer (1971) 1.37
Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med (1980) 1.37
The soft x-ray instrument for materials studies at the linac coherent light source x-ray free-electron laser. Rev Sci Instrum (2012) 1.36
Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine. Clin Pharmacol Ther (1972) 1.35
Dose schedule and antitumor studies of arabinosyl cytosine (NSC 63878). Cancer Res (1969) 1.33
Role of murine tumor models in cancer treatment research. Cancer Res (1986) 1.30
First outbreak of Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in Germany. Eur J Clin Microbiol Infect Dis (2010) 1.29
Studiesof a patient isolator unit and prophylactic antibiotics in cancer chemotherapy. General techniques and preliminary results. Cancer (1968) 1.28
The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem Pharmacol (2001) 1.27
Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie (2003) 1.27
Combination chemotherapy in advanced Hodgkin's disease. Induction and maintenance of remission. Ann Intern Med (1973) 1.27
The National Cancer Chemotherapy Program. Science (1982) 1.26
Coherence properties of individual femtosecond pulses of an x-ray free-electron laser. Phys Rev Lett (2011) 1.26
Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. Cancer Res (1974) 1.25
The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood (1965) 1.23
Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res (1987) 1.23
double-time is identical to discs overgrown, which is required for cell survival, proliferation and growth arrest in Drosophila imaginal discs. Development (1999) 1.23
Progress and perspectives in the chemotherapy of acute leukemia. Adv Chemother (1965) 1.22
The effect of skin homograft rejection on recipient and donor mixed leukocyte cultures. J Exp Med (1965) 1.22
Cell proliferation in human melanoma. J Clin Invest (1970) 1.21
shaven and sparkling are mutations in separate enhancers of the Drosophila Pax2 homolog. Development (1998) 1.18
Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamide. Cancer (1972) 1.18
Osteosarcoma: fifteen years later. N Engl J Med (1985) 1.17
Nanofocusing of hard X-ray free electron laser pulses using diamond based Fresnel zone plates. Sci Rep (2011) 1.16
Radioiodination of proteins and lipoproteins using N-bromosuccinimide as oxidizing agent. Anal Biochem (1988) 1.16
Pathophysiology, clinical manifestations and therapy of consumption-coagulopathy ("Verbrauchskoagulopathie"). Am J Cardiol (1967) 1.15
Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines. Cancer Res (1986) 1.15
Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol (1992) 1.15
L-dopa: selective toxicity for melanoma cells in vitro. Science (1977) 1.15
Adverse effects of intrathecal methotrexate in children with acute leukemia in remission. Blood (1975) 1.14
New approaches to cancer chemotherapy with methotrexate. N Engl J Med (1975) 1.12
Chemotherapy of malignant lymphoma with adriamycin. Cancer Res (1973) 1.11
Pharmacokinetics of actinoymcin D in patients with malignant melanoma. Clin Pharmacol Ther (1975) 1.10
High-dose ifosfamide with mesna uroprotection: a phase I study. J Clin Oncol (1990) 1.09
Comparison of three methods of central-nervous-system prophylaxis in childhood acute lymphoblastic leukaemia. Lancet (1980) 1.09
Passover: a gene required for synaptic connectivity in the giant fiber system of Drosophila. Cell (1993) 1.07
Prognotic significance of pretreatment proliferative activity in adult acute leukemia. Cancer (1977) 1.06
Selective incorporation of L-3,4-dihydroxyphenylalanine by S-91 Cloudman melanoma in vitro. Cancer Res (1977) 1.05
Formation of a new dynamical mode in -uranium observed by inelastic x-ray and neutron scattering. Phys Rev Lett (2006) 1.05
Protected environment-prophylactic antibiotic program in the chemotherapy of acute leukemia. Am J Med Sci (1971) 1.05
[Experimental bone scintigraphy in animals]. Nucl Med (Stuttg) (1970) 1.04
A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol (1989) 1.04
Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol (1994) 1.03
Design of compounds having enhanced tumour uptake, using serum albumin as a carrier--Part II. In vivo studies. Int J Rad Appl Instrum B (1992) 1.02
Endothelin-1 in subarachnoid hemorrhage: An acute-phase reactant produced by cerebrospinal fluid leukocytes. Stroke (2000) 1.02
High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med (1980) 1.02
Simplified cell labelling with indium-111 acetylacetone. Br J Radiol (1979) 1.02
Development of methotrexate resistance in a human squamous cell carcinoma of the head and neck in culture. Proc Natl Acad Sci U S A (1984) 1.01
Post-surgical follow-up (by ELISA and immunoblotting) of cured versus non-cured cystic echinococcosis in young patients. Parasitology (2007) 1.01
Neoadjuvant chemotherapy in marginally resectable stage III M0 non-small cell lung cancer: long-term follow-up in 41 patients. J Surg Oncol (1989) 1.01
Alkylating agent resistance: in vitro studies with human cell lines. Proc Natl Acad Sci U S A (1985) 1.01
Pharmacologic studies of the antitumor agent 5-(dimethyltriazeno)imidazole-4-carboxamide. Cancer Res (1968) 1.01
The Fibrin Assay Comparison Trial (FACT): evaluation of 23 quantitative D-dimer assays as basis for the development of D-dimer calibrators. FACT study group. Thromb Haemost (2001) 1.00
The Philadelphia chromosome and chronic myelogenous leukemia. J Natl Cancer Inst (1966) 1.00
Combination chemotherapy with adriamycin-cyclophosphamide for advanced ovarian carcinoma. Cancer (1980) 1.00